Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ABBV-453
i
Other names:
ABBV-453
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
AbbVie
Drug class:
Bcl2 inhibitor
Related drugs:
‹
venetoclax (416)
paclitaxel (178)
albumin-bound paclitaxel (67)
ABT 263 (19)
APG-1252 (8)
APG-2575 (7)
micellar paclitaxel (3)
APG1244 (2)
AR160 (2)
BGB-11417 (2)
ABBV-167 (1)
paclitaxel oral (1)
oral paclitaxel/encequidar (1)
AT 101 (1)
S55746 (1)
AZD0466 (0)
AZD4320 (0)
BGB-21447 (0)
BP1002 (0)
Bcl-2 Family Inhibitors (0)
paclitaxel polymeric micelle formulation (0)
paclitaxel liposomal (0)
FCN-338 (0)
FCN-683 (0)
oblimersen (0)
KLTi (0)
L105 (0)
LP-108 (0)
LP-118 (0)
liposomal paclitaxel (0)
MRX34 (0)
paclitaxel nanoformulation (0)
paclitaxel-hyaluronic acid conjugate (0)
paclitaxel poliglumex (0)
S65487 (0)
SPC2996 (0)
TQB3909 (0)
TW-37 (0)
ZN-d5 (0)
bisphosphonate bound paclitaxel (0)
FID-007 (0)
GX 15-070 (0)
QR 207 (0)
ANG1005 (0)
PNT2258 (0)
ONT-701 (0)
venetoclax (416)
paclitaxel (178)
albumin-bound paclitaxel (67)
ABT 263 (19)
APG-1252 (8)
APG-2575 (7)
micellar paclitaxel (3)
APG1244 (2)
AR160 (2)
BGB-11417 (2)
ABBV-167 (1)
paclitaxel oral (1)
oral paclitaxel/encequidar (1)
AT 101 (1)
S55746 (1)
AZD0466 (0)
AZD4320 (0)
BGB-21447 (0)
BP1002 (0)
Bcl-2 Family Inhibitors (0)
paclitaxel polymeric micelle formulation (0)
paclitaxel liposomal (0)
FCN-338 (0)
FCN-683 (0)
oblimersen (0)
KLTi (0)
L105 (0)
LP-108 (0)
LP-118 (0)
liposomal paclitaxel (0)
MRX34 (0)
paclitaxel nanoformulation (0)
paclitaxel-hyaluronic acid conjugate (0)
paclitaxel poliglumex (0)
S65487 (0)
SPC2996 (0)
TQB3909 (0)
TW-37 (0)
ZN-d5 (0)
bisphosphonate bound paclitaxel (0)
FID-007 (0)
GX 15-070 (0)
QR 207 (0)
ANG1005 (0)
PNT2258 (0)
ONT-701 (0)
›
Associations
News
Trials
Filter by
Latest
1m
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
P1, N=34, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | N=360 --> 34 | Trial completion date: Aug 2026 --> Dec 2025 | Trial primary completion date: Aug 2026 --> Feb 2024
1 month ago
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Adverse events • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
Chr t(11;14)
|
lenalidomide • Darzalex (daratumumab) • dexamethasone • ABBV-453
5ms
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov)
P1, N=80, Recruiting, AbbVie | Not yet recruiting --> Recruiting
5 months ago
Enrollment open • Adverse events
|
Gazyva (obinutuzumab) • ABBV-453
9ms
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov)
P1, N=80, Not yet recruiting, AbbVie
9 months ago
New P1 trial • Adverse events
|
Gazyva (obinutuzumab) • ABBV-453
10ms
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
P1, N=360, Recruiting, AbbVie | Trial completion date: Apr 2026 --> Aug 2026 | Trial primary completion date: Apr 2026 --> Aug 2026
10 months ago
Trial completion date • Trial primary completion date • Adverse events • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
Chr t(11;14)
|
lenalidomide • Darzalex (daratumumab) • dexamethasone • ABBV-453
1year
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
P1, N=360, Recruiting, AbbVie | N=48 --> 360
1 year ago
Enrollment change • Adverse events • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
Chr t(11;14)
|
lenalidomide • Darzalex (daratumumab) • dexamethasone • ABBV-453
over1year
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
P1, N=48, Recruiting, AbbVie | N=21 --> 48
over 1 year ago
Enrollment change • Adverse events • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
Chr t(11;14)
|
lenalidomide • Darzalex (daratumumab) • ABBV-453
over1year
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
P1, N=21, Recruiting, AbbVie | Trial primary completion date: Aug 2025 --> Apr 2026
over 1 year ago
Trial primary completion date • Adverse events • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
Chr t(11;14)
|
ABBV-453
over2years
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
P1, N=21, Recruiting, AbbVie | Not yet recruiting --> Recruiting
over 2 years ago
Enrollment open • Adverse events • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
ABBV-453
over2years
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
P1, N=21, Not yet recruiting, AbbVie
over 2 years ago
New P1 trial • Adverse events • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
ABBV-453
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login